371 Second, pharmacological reactivation of mutant p53 uses small molecules like APR-246, COTI-2, and arsenic trioxide (Table 7), which bind to mutant p53 and convert the protein to a p53 wild-type-like conformation, thus restoring wild-type DNA-binding properties
All detailed data are presented in Table 2
Final pricing will depend on approval status, insurance coverage, and any manufacturer savings programs that may become available
By keeping a close eye on patients and adjusting dosages, we aim for the best results and safety
Months 6-12 and Beyond: Long-Term Progress Extended use allows for continued slow progress in body composition
Dietary reference intakes for energy, carbohydrates, fiber, fat, fatty acids, cholesterol, protein, and amino acids